About NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company committed to the identification and development of biologics for diabetes, obesity and other cardio-metabolic diseases.
NGM Biopharmaceuticals Patents
NGM Biopharmaceuticals has filed 105 patents.
Molecular biology, Monoclonal antibodies, DNA, RNA, Genetics
Molecular biology, Monoclonal antibodies, DNA, RNA, Genetics
Latest NGM Biopharmaceuticals News
Sep 22, 2023
Disclosures: Loomba reports financial relationships with 89bio, Aardvark Therapeutics, Allergan, Altimmune, Amgen Inc., Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CohBar, Eli Lilly, Galectin, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Glympse bio, Hanmi Pharmaceutical, Hightide, Inipharm, Intercept Pharmaceuticals, Inventica, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Kowa Company LTD., Liponexus, Madrigal Pharmaceuticals, Merck, Metacrine Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, P30DK120515, Pfizer, Sagiment Biosciences, Sonic Incytes, Terns Pharmaceuticals, Theratechnologies Inc. and Viking Therapeutics. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact firstname.lastname@example.org . Back to Healio Key takeaways: Improvement in fibrosis occurred in up to 27% of patients treated with pegozafermin vs. 7% on placebo. Nonalcoholic steatohepatitis resolved in up to 37% of patients treated with pegozafermin vs. 2% on placebo. Subcutaneous pegozafermin at weekly and biweekly doses improved fibrosis at 24 weeks vs. placebo among patients with biopsy-confirmed nonalcoholic steatohepatitis, supporting the therapy’s advancement to phase 3 development, data showed. “Pegozafermin, a long-acting glycopegylated recombinant fibroblast growth factor 21 analogue, is being developed for the treatment of NASH and severe hypertriglyceridemia,” Rohit Loomba, MD, MHSc, director of the NAFLD Research Center at the University of California, San Diego, and colleagues wrote in The New England Journal of Medicine. “A phase 1b-2a study involving patients with NASH did not show safety concerns and suggested that pegozafermin therapy may improve hepatic steatosis, markers of inflammation and fibrosis, circulating lipid levels and glycemic control.” In a phase 2b, randomized, double-blind, placebo-controlled trial at 61 U.S. sites, researchers enrolled 222 patients (mean age, 55.6 years; 39% men) with noncirrhotic, biopsy-confirmed NASH and moderate to severe fibrosis. Participants received subcutaneous pegozafermin 15 mg (n = 21) or 30 mg (n = 73) weekly, pegozafermin 44 mg (n = 57) biweekly or placebo (n = 71) for 24 weeks. Studied outcomes included improvement in fibrosis of at least one stage with no worsening of NASH, NASH resolution without worsening of fibrosis and safety of pegozafermin. At 24 weeks, 7% of patients in the placebo group had improved fibrosis compared with 22% in the pegozafermin 15 mg group (14 percentage points difference; 95% CI, –9 to 38), 26% in the 30 mg group (19 percentage points difference; 95% CI, 5-32) and 27% in the 44 mg group (20 percentage points difference; 95% CI, 5-35). Researchers also reported NASH resolution without worsening of fibrosis among 37% of patients in the 15 mg group (35 percentage points difference; 95% CI, 10-59), 23% in the 30 mg group (21 percentage points difference; 95% CI, 9-33) and 26% in the 44 mg group (24 percentage points difference; 95% CI, 10-37), compared with 2% in the placebo group. Further, results showed a drop in nonalcoholic fatty liver disease activity score of at least 2 points without worsening of fibrosis among 37%, 65% and 62% of patients in the 15 mg, 30 mg and 44 mg groups, respectively, vs. 24% in the placebo group, as well as at least a 50% reduction in liver fat among 63% in the 30 mg group and 58% in the 44 mg group vs. 12% on placebo. The most common adverse events associated with treatment were nausea and diarrhea. “In this phase 2b trial, pegozafermin treatment for 24 weeks led to improvements in fibrosis with both weekly and every 2-week administration in patients with biopsy-confirmed NASH,” Loomba and colleagues concluded. “A potential for administration once every 2 weeks may increase patient convenience and adherence to treatment.” They continued: “Results of this trial may be informative for guiding dose selection for larger and longer phase 3 trials involving patients with NASH.” Read more about
NGM Biopharmaceuticals Frequently Asked Questions (FAQ)
When was NGM Biopharmaceuticals founded?
NGM Biopharmaceuticals was founded in 2008.
Where is NGM Biopharmaceuticals's headquarters?
NGM Biopharmaceuticals's headquarters is located at 630 Gateway Boulevard, South San Francisco.
What is NGM Biopharmaceuticals's latest funding round?
NGM Biopharmaceuticals's latest funding round is IPO.
How much did NGM Biopharmaceuticals raise?
NGM Biopharmaceuticals raised a total of $290.78M.
Who are the investors of NGM Biopharmaceuticals?
Investors of NGM Biopharmaceuticals include The Column Group, Prospect Venture Partners, Tichenor Ventures, Topspin Consumer Partners, Merck & Co. and 5 more.
Who are NGM Biopharmaceuticals's competitors?
Competitors of NGM Biopharmaceuticals include Noveome Biotherapeutics, Albireo Pharma, Catalyst Biosciences, MaxCyte, Oceanit, Animal Cell Therapies, Vernalis, Molmed, Hawaii Biotech, Akron Biotechnology and 70 more.
Compare NGM Biopharmaceuticals to Competitors
is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Avestha Gengraine Technologies is a biotechnology & bioinformatics company, focusing on the convergence between food, pharmaceuticals and clinical genomics leading to preventive personalized medicine. . Avesthagen was founded by Dr. Villoo Morawala-Patell in 1998, on the premise that the time was ripe for India to establish its own research and discovery based biotechnology industry. Avesthagen aims to provide solutions for global challenges in agriculture & health problems in the areas of degenerative conditions, metabolic disorders and infectious diseases.
Cell Line Genetics aims to provide services and products to support research institutions, as well as biotechnology and pharmaceutical companies focused on embryonic stem cell and cancer research.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Noveome Biotherapeutics is a clinical-stage biopharmaceutical company. It focuses on developing biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. It engages in completing a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs). Noveome Biotherapeutics was formerly known as Stemnion. It was founded in 2000 and is based in Pittsburgh, Pennsylvania.